Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07608796 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

JAK Signaling in Depression and Cognition in Male Football Players

Study acronym: JAK DC in Play
StatusRecruiting
PhasePhase 2
Started2026-10
View on ClinicalTrials.gov ↗

Amendment history

2026-09-25
Recruitment opened
2026-08-18
Study Status, Study Description, Outcome Measures, Eligibility v1
Start date2026-06→2026-09
Eligibility criteria-13 characters
Inclusion Criteria: willing and able to give written informed consent males >10playing years of playingtackle football (for at least 111 year in the NFL)years 4030-55 years of age Current Diagnostic and Statistical Manual ( [...]
Secondary endpoints10 to 11 entries
PlasmaInflammatory inflammatorycytokines biomarkers(IL-1, IL-6, TNF) High-sensitivity (hs) CRP
2026-05-20
Original filing
Emory University
371 trials monitored
See 23 trials at risk
Depression
2,976 trials monitored
See 162 trials at risk
This study is being done to learn more about the role of inflammation in depressive and cognitive symptoms in patients with depression who have played at least 11 years of organized tackle football. This will be evaluated using a medication called baricitinib, which blocks one aspect of inflammation.
Trial Details
NCT Number NCT07608796
Lead Sponsor Emory University
Conditions Depressive Symptoms, Cognitive Symptom
Enrollment 30 participants
Start Date 2026-10
Primary Completion 2027-10 (estimated)
Study Completion 2027-10 (estimated)
Updated on ClinicalTrials.gov 2026-09-24